TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01514942

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Myo-inositol + Folic acid
Description: Myo-inositol (2g) Folic acid (200mcg) (2 per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Myo-inositol + Folic acid
Description: Myo-inositol (2g) Folic acid (200mcg) (2 per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: D-chiro-inositol, manganese, folic acid, vit B12
Description: D-Chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: D-chiro-inositol, manganese, folic acid, vit B12
Description: D-chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)

Intervention type: DRUG
Group type: OTHER
Intervention: Folic acid, vit B12
Description: Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)

Intervention type: DRUG
Group type: OTHER
Intervention: Folic acid, vit B12
Description: Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
Study: NCT05935592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based comic and newsletters
Description: Web-based comic and health messages (child component) and health newsletters (parent component)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Didactic health information
Description: Web-based newsletters (for child and parent) by email and/or text
Study: NCT06045221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orforglipron
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide
Description: Administered orally
Study: NCT04298203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phentermine-Topiramate
Description: The study medication to be tested for this study is a combination of phentermine and topiramate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Phentermine-Topiramate
Description: The study medication to be tested for this study is a combination of phentermine and topiramate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal Replacement Therapy
Description: The first six weeks of the study, subjects will receive meal replacement therapy in an effort to reduce their BMI by at least 5%.
Study: NCT05027815

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
Description: cryopreserved cellular therapy product in cryostor CS5, for IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
Description: cryopreserved cellular therapy product in cryostor CS5, for IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
Description: cryopreserved cellular therapy product in cryostor CS5, for IV infusion
Study: NCT04921800

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Anterior Cervical Discectomy & Fusion
Description: Participants are undergoing previously scheduled anterior cervical discectomy \& fusion for single level or multiple level cervical disease

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Application of ADAM mechanoacoustic skin sensor
Description: Applying the ADAM sensor to the suprasternal notch following surgery to allow for collection of the anatomical data
Study: NCT04282629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milrinone Injection
Description: administration of milrinone (0.75 μg / kg / min, intravenous) from Day 4 to Day 14

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: administration of placebo (intravenous glucose 5%) from Day 4 to Day 14
Study: NCT05183347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: BI 1291583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: BI 1291583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: BI 1291583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1291583
Description: BI 1291583

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04298203

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A pill that looks like Phentermine-Topiramate but has no active medication.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A pill that looks like Phentermine-Topiramate but has no active medication.
Study: NCT06529796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXP
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXP
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXP
Description: Tablet for oral administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IXP
Description: Tablet for oral administration.
Study: NCT04883242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skeletal Survey X-Ray
Description: Undergo skeletal x-ray

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06542900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation (DBS)
Description: The DBS lead is stereotactically introduced into the target in the brain (SCC, VC/VS, ALIC, ITP, NAc, LHb, MFB, or other unreported nuclei targets) and fixed to the skull; the lead is then connected to a neurostimulator implanted subcutaneously in the subclavicular region.
Study: NCT06517095

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: improved capsular polishing
Description: In the polished group,utilize the OVDs to partially fill the peripheral capsule, causing the central posterior capsule to bulge, and then employ the double-ended Whitman Shepherd capsular polisher to meticulously polish both the anterior and equator of the capsule. This process also allows for simultaneous polishing of a portion of the posterior capsule. By rotating the polisher 180°along one side, followed by switching ends to cover the remaining 180° range, even the main incision site can be effectively addressed due to its curved tip design.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: the conventional I/A polishing
Description: the conventional I/A polishing the capsule
Study: NCT06431334

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Amino Acid Intake
Description: Amino acid intakes will vary between 0.5 to 2.8 g/kg/d
Study: NCT05801861

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active 10-Hz TMS to the parietal cortex
Description: The active 10-Hz TMS group will receive 10hz TMS stimulation in the first TMS session, and single pulse TMS in the second TMS session. Participants in the active stimulation group will receive 10-Hz TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active single pulse TMS to the parietal cortex
Description: The active single pulse TMS group will receive single pulse TMS stimulation in the first and second TMS session. Participants in the active stimulation group will receive single pulse TMS to right parietal cortex. The TMS target will be based on subject specific anatomical MRI images (diffusion imaging). TMS will be delivered using a robotic neuronavigation system (Smartmove, ANT). Stimulation intensity will be standardized at 110% of RMT and adjusted to the skull to cortical surface based on e-field calculations (simnibs). Stimulation will be delivered to the right parietal cortex using an active/placebo figure-8 coil, an magventure TMS device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham 10-Hz TMS to the right parietal cortex
Description: The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham single-pulse rTMS the rigt parietal cortex
Description: The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
Study: NCT04248946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS alters neural excitability in a polarity-specific manner via a weak direct electric current delivered through electrodes placed on the scalp. There are 3 types of stimulation: anodal, cathodal, and sham. In anodal tDCS, the positive electrode is placed over the target brain area to increase neuronal excitability. In cathodal tDCS, the negative electrode is placed over the target brain area to decrease neuronal excitability. Sham tDCS emulates the physical sensations of active (anodal/cathodal) tDCS but current is only delivered for a short period of time and is not enough to cause any neuromodulations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS alters neural excitability in a polarity-specific manner via a weak direct electric current delivered through electrodes placed on the scalp. There are 3 types of stimulation: anodal, cathodal, and sham. In anodal tDCS, the positive electrode is placed over the target brain area to increase neuronal excitability. In cathodal tDCS, the negative electrode is placed over the target brain area to decrease neuronal excitability. Sham tDCS emulates the physical sensations of active (anodal/cathodal) tDCS but current is only delivered for a short period of time and is not enough to cause any neuromodulations
Study: NCT06086431

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium chloride
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the erector spine plane block
Study: NCT05201326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab，Irinotecan and Re-radiotherapy
Description: All patients with recurrent glioblastoma will accept irinotecan and bevacizumab combined with re-radiotherapy .
Study: NCT06086431

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1mg/kg Dexamethasone for the erector spine plane block

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the erector spine plane block
Study: NCT05613959

Intervention type: DEVICE
Intervention: Veress +
Description: The Veress+ safety mechanism was used

Intervention type: DEVICE
Intervention: Conventional Veress
Description: The Conventional Veress Needle was used
Study: NCT05718674

Intervention type: PROCEDURE
Intervention: Extracorporeal Photopheresis
Description: ECP is performed by collecting leucocytes from the patient through leukopheresis and incubating them with 8-MOP and UVA in extracorporeal circulation. The treatment steps are the collection of leucocytes, photoactivation and subsequent reinfusion of the treated cells.
Study: NCT06079996

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAFFEINE GUM
Description: Observing the effect of chewing gum on the performance of female softball players.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CAFFEINE GUM
Description: Observing the effect of chewing gum on the performance of female softball players.
Study: NCT06423352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zilebesiran
Description: Zilebesiran administered by subcutaneous (SC) injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered by SC injection
Study: NCT05313399

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Palatal Crib
Description: An intraoral appliance approach can be used as an adjunct method to stop the habit. Appliances consisting of cribs in the anterior region are very efficient as reminders and physical restrainers. The palatal crib works as an obstacle in non-nutritive sucking and maintains the tongue in a more retruded position, halting its interposition between the incisors.
Study: NCT05003258

Intervention type: DEVICE
Group type: OTHER
Intervention: Intravitreal injection of Dexamethasone implant
Description: Intravitreal injection of Dexamethasone implant
Study: NCT05417594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9574
Description: Participants will receive AZD9574 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9574
Description: Participants will receive AZD9574 orally.
Study: NCT05313399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: bonded spur
Description: Spur appliances change tongue action, close the open bite, and boost treatment stability, as it induces a permanent modification of the tongue's anterior rest posture by altering orofacial function, resulting in a change in form. Finally, the spur adjusts the sensory input to the brain. This proprioceptive change leads to an altered motor response, resulting in a new normal tongue rest posture (change in function) that allows the incisors to erupt
Study: NCT06473116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoprenaline Only Product
Description: Administration of intravenous isoprenaline of 600 mikrograms immediately after recognition of asystole in bystander-witnessed out-of-hospital cardiac arrest

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoprenaline Only Product
Description: Administration of intravenous isoprenaline of 600 mikrograms immediately after recognition of asystole in bystander-witnessed out-of-hospital cardiac arrest
Study: NCT04727528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: Investigational medicinal product

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium zirconium cyclosilicate
Description: Investigational medicinal product
Study: NCT05417594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9574
Description: Participants will receive AZD9574 orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Participants will receive temozolomide orally.
Study: NCT04727528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Plabeco comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Plabeco comparator
Study: NCT05645302

Intervention type: DRUG
Intervention: Lidocaine Cataplasms
Description: The main ingredient of this product is lidocaine, the cream surface is white or almost white, the cream is evenly spread on the back, and the cream surface is covered with film.
Study: NCT06267820

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: analgesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: analgesia
Study: NCT05417594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]AZ1419 3391
Description: Participants will receive \[11C\]AZ1419 3391 intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]AZ1419 3391
Description: Participants will receive \[11C\]AZ1419 3391 intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]AZ1419 3391
Description: Participants will receive \[11C\]AZ1419 3391 intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan (Dato-DXd)
Description: Participants will receive Dato-DXd intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab Deruxtecan (T-DXd)
Description: Participants will receive T-DXd intravenously.
Study: NCT06426277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brazilian Diabetes Prevention Program (face-to-face care)
Description: A Program structured in 28 visits (in group and individual) and 21 contacts (through phone calls or video calls) to guide the improvement of diet quality, self-care, and regular practice of physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Hypocaloric diet prescription

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brazilian Diabetes Prevention Program (remote care)
Description: A Program structured in 49 contacts delivered through telehealth (through phone calls or video calls between professional and participant) to guide the improvement of diet quality, self-care, and regular practice of physical activity
Study: NCT05947500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool
Study: NCT05701280

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: Deep Brain Stimulation (DBS) of the dentate nucleus area of the cerebellum plus motor rehabilitation to improve upper-extremity function.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Motor rehabilitation to improve upper-extremity function.
Study: NCT05205499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System
Description: Subjects in this arm will be treated with IBS
Study: NCT05947500

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT06144112

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: fresh frozen plasma
Description: transfusion of fresh frozen plasma

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: prothrombin complex concentrate
Description: prothrombin complex concentrate administration
Study: NCT05927077

Intervention type: PROCEDURE
Intervention: planned surgery for weight reduction
Description: planned surgeries will be used to collect study material to determine chemical patterns in the study participants from the different geographical regions

Intervention type: PROCEDURE
Intervention: planned surgery for weight reduction
Description: planned surgeries will be used to collect study material to determine chemical patterns in the study participants from the different geographical regions

Intervention type: PROCEDURE
Intervention: planned surgery for weight reduction
Description: planned surgeries will be used to collect study material to determine chemical patterns in the study participants from the different geographical regions
Study: NCT05947500

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study: NCT06082310

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Two HIIT modalities

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Two HIIT modalities
Study: NCT05114187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education Intervention
Description: Participants in the intervention group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~1. Ten selected multimedia e-learning lessons;~2. A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete the intervention. The total time to complete is approximately 5-6 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education Control
Description: Participants in the control group will be provided e-learning about dementia and promoting brain health, consisting of the following components:~1. One selected multimedia e-learning lesson;~2. A series of 16 'micro-learning' emails (2 emails/week) with small segments of content to reinforce the material from the lessons.~Participants will have 8-weeks to complete. The total time to complete is approximately 1-2 hours.~Note: All participants will receive access to all e-learning at the conclusion of the study.
Study: NCT05136235

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Echocardiography
Description: There will be screened for pulmonary hypertension by means of serial echocardiographies during the study period

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: NT-proBNP
Description: At 36 weeks postmenstrual age there will be screened for pulmonary hypertension by means of an NT-proBNP measurement in a blood sample